Skip to main content
KPTI logo

KPTI · Karyopharm Therapeutics Inc.

Track KPTI — free
$0.02 +0.00 (+3.45%) At close · Nov 11
Market Cap
$408,266
Shares
22.68M
Volume · Nov 11 8.28M Avg daily vol (3M) 8.53M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.02 Open$0.01 Day$0.01–0.02 52W close$0.02–10.67 Avg vol 30d16.9M Short int8.2M · 36.3% of shares · 1.1d Short vol49% Last earningsAug 13, 2026 DataJan 2020–Nov 2026 Filing10-Q · Aug 13

Latest documents

2026
Nov 13
Late filing notice NT 10-Q
Bankruptcy delays quarterly filing; Nasdaq suspends trading

Karyopharm Therapeutics Inc. filed Chapter 11 on November 2, 2026, cannot file its Form 10-Q, and Nasdaq suspended trading on November 11, 2026. Its plan cancels equity without distribution, with Ayrmid transaction expected to close in first quarter of 2027.

5 source passages
Karyopharm Therapeutics Inc. (the “Company”) has determined that it is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 (the “Quarterly Report”) by the prescribed filing date or the five-day extension permitted by the rules of the Securities and Exchange Commission (the “SEC”). As previously announced, on November 2, 2026, the Company and its subsidiary KPT Texas LLC (together with the Company, the “Debtors”) filed voluntary petitions (the “Bankruptcy Petitions”) under Chapter 11 of title 11 of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the Southern District of Texas, Houston Division (such court, the “Court” and such cases, the “Cases”). On November 11, 2026, the Nasdaq Stock Market (“Nasdaq”) suspended trading of the Company’s common stock. The Prepackaged Plan provides that holders of the Company’s common stock and the 0% Series A Convertible Perpetual Preferred Stock will not receive any payment or other distribution on account of such securities. The Company expects the Ayrmid transaction to close in the first quarter of 2027, subject to the conditions described in the Restructuring Support Agreement and the Prepackaged Plan. Open the document at this passage
Nov 5
Current report 8-K Events of Nov 4
Nasdaq delisting follows Karyopharm Chapter 11 filing

After Karyopharm Therapeutics Inc. filed Chapter 11 petitions on November 2, 2026, Nasdaq notified it that securities will be delisted. Trading will suspend November 11, 2026; it will not appeal and expects existing equity securities to have no value.

Delisting notice or listing transfer
5 source passages
As previously disclosed, on November 2, 2026, Karyopharm Therapeutics Inc. (the “Company”) and its subsidiary, KPT Texas LLC (together with the Company, the “Debtors”) filed voluntary petitions (the “Bankruptcy Petitions”) under Chapter 11 of title 11 of the United States Code On November 4, 2026, the Company received written notice (the “Delisting Notice”) from the staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, as a result of the Bankruptcy Petitions and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, the staff of Nasdaq determined that the Company’s securities will be delisted from Nasdaq. Trading of the Company’s common stock will be suspended on Nasdaq at the opening of business on November 11, 2026 and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the securities from listing and registration on Nasdaq. The Company will not appeal this determination. In particular, the Company expects that its existing equity securities will have no value and that holders of such securities will experience a complete loss on their investment. Open the document at this passage
Nov 2
Current report 8-K
Ayrmid merger advances through Chapter 11, equity expected worthless

Karyopharm Therapeutics Inc. plans a merger with Ayrmid Ltd. and filed Chapter 11 petitions. The deal is expected to close in the first quarter of 2027 with up to $55 million in DIP financing; equity is expected to have no value.

Regulation FD disclosure
5 source passages
Karyopharm Therapeutics Inc. ("Karyopharm") announced today it has entered into a Restructuring Support Agreement with its existing lenders and noteholders and other key stakeholders, which provides for a merger between Ayrmid Ltd. ("Ayrmid") and a reorganized Karyopharm (the "Transaction"). To implement the Transaction, Karyopharm has filed voluntary petitions under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas. The Transaction is expected to close in the first quarter of 2027, subject to the conditions described in the Chapter 11 plan. In connection with this process, Karyopharm has secured commitments for up to $55 million in debtor-in-possession ("DIP") financing from its existing secured lenders. The Company expects that its existing equity securities will have no value and that holders of such securities will experience a complete loss on their investment. Open the document at this passage
Oct 22
Current report 8-K
Other events

Karyopharm Therapeutics Inc. further extended the end of its forbearance period from 11:59 p.m., Eastern time, on October 22, 2026 to 11:59 p.m., Eastern time, on November 1, 2026, absent earlier termination.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$146.62M
Trailing 12 months
Net income (TTM)
−$224.74M
Trailing 12 months
Revenue growth YoY
-11.9%
Year over year
Operating margin
-56.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+235.7%
Year over year · more shares
Price change (1Y)
-99.7%
Trailing year
Short interest
36.3%
Latest settlement · 1.1 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 13, 2026
Q2 FY26

TL;DR. Karyopharm remains on track to submit its sNDA in August seeking accelerated approval of selinexor plus ruxolitinib in myelofibrosis, while reaffirming its 2026 revenue guidance; however, the XPORT-EC-042 Phase 3 in endometrial cancer failed to meet its primary endpoint, and the company warned that without additional financing or a lender waiver, a $15.8 million September 10 payment would push liquidity below its $10 million covenant and trigger a default.

Bullish
  • + Company remains on track to submit sNDA in August for selinexor plus ruxolitinib in myelofibrosis under accelerated approval, with FDA written feedback that SVR35 appears to qualify as a reasonably likely surrogate endpoint.
  • + SVR35 responses with the selinexor plus ruxolitinib combination were nearly double those of ruxolitinib alone at week 24 and were rapid, deep, and sustained through week 36.
  • + Phase 3 SENTRY overall survival hazard ratio was 0.43 and SVR35 was shown to predict overall survival, supporting the regulatory package.
  • + U.S. XPOVIO net product revenue rose to $30.8 million in Q2 2026 from $29.7 million in Q2 2025, and R&D and SG&A expenses declined year over year.
Bearish
  • − Cash runway only extends into September 2026, and a $15.8 million term loan payment due September 10, 2026 without additional financing or a lender waiver would push liquidity below the $10 million minimum covenant and trigger an event of default.
  • − Q2 2026 net loss widened to $67.0 million from $37.3 million in the prior-year period, driven primarily by $32.1 million of non-cash other expense from mark-to-market adjustments.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bearish Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −100%
below
Price vs 50-day avg −98%
below
RSI (14) 28
oversold
MACD trend Positive
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −94%
trailing
6-month return −100%
trailing
YTD return −100%
this year
Relative strength −102%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $1 › 200d $6 — 200d above 50d
Institutional flow Distributing
-8% holders QoQ · +21 funds added
Insider flow Distributing
Net -$2.1K over 90 days · 100% sells
Short interest Rising
36.29% of shares out · ▲ +13.3% MoM · 1.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
92 holders — mid 3-yr range
Squeeze score 58
elevated · 0–100
Fundamentals
Poor
Revenue growth +1%
Y/Y
EPS growth −28%
Y/Y
Free cash flow $-75.4M
Quant / Vol
risk profile
Very High
Volatility 185%
annualized · 1-yr
Max drawdown −100%
past year
ATR 687.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 4 of last 4
Latest guidance · from the 8-K filed Aug 13, 2026
Total revenue · full year 2026 Maintained $130M – $150M
May 14, 2026 $130M – $150M changed to Aug 13, 2026 $130M – $150M
prior FY $146.07M midpoint −4.2% Y/Y
U.S. XPOVIO net product revenue · full year 2026 Maintained $115M – $130M
May 14, 2026 $115M – $130M changed to Aug 13, 2026 $115M – $130M
R&D and selling, general and administrative (SG&A) expenses · full year 2026 Maintained $230M – $245M
May 14, 2026 $230M – $245M changed to Aug 13, 2026 $230M – $245M
Guided vs delivered · last 4 settled
Total revenue full year 2025
guided $140M – $155M
$146.07M In line
Total revenue full year 2024
guided $145M – $160M
$145.24M In line
Total revenue full year 2023
guided $145M – $160M
$146.03M In line
Total revenue full year 2022
guided $155M – $165M
$157.07M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−100% Bearish
Price vs 50-day avg
−98% Bearish
RSI (14)
28 Neutral
MACD trend
Positive Bullish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross) No cross
50d $1 › 200d $6 — 200d above 50d
Institutional flow Distributing
-8% holders QoQ · +21 funds added
Insider flow Distributing
Net -$2.1K over 90 days · 100% sells
Short interest Rising
36.29% of shares out · ▲ +13.3% MoM · 1.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
92 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0 Now $0 · 0% Range high $11
vs 200-day avg -100% vs 50-day avg -98%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Total license and other revenue 2.66M the three months ended June 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
KPTI
Karyopharm Therapeutics Inc.
this stock
$408,266 -99.8% +0.6% — 36.3%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
92
% held
76.4%
Net QoQ
-3.8M sh
Top holder
ADAGE CAPITAL PARTNERS GP…
Held Float
View
Held by Funds
Fund positions
105
View
Short & Settlement
Short Interest Rising
Shares short
8.2M
Days to cover
1.1d
Change
+965.2K sh
View
Short Volume
Short vol %
49%
As of
Nov 10, 2026
Short Total
View
Fails to Deliver
FTD shares
1.8K
Value
$1.5K
As of
Oct 5, 2026
View
Off-Exchange
Off-exchange %
61.9%
Week of
Oct 5, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$2.1K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$146.1M
Net income (FY)
$-196.0M
EPS diluted
$-17.93
View
Filings
SEC Filings
Latest
NT 10-Q
Filed
Nov 13, 2026
This year
31

Karyopharm Therapeutics Inc. filed Chapter 11 on November 2, 2026, cannot file its Form 10-Q, and Nasdaq suspended trading on November 11, 2026. Its plan cancels equity without distribution, with Ayrmid transaction expected to close in first quarter of 2027.

View
Exempt Offerings
Offering
$165.0M
Filed
Dec 8, 2022
View
Earnings & Events
Webcasts
Last webcast
Aug 13, 2026
View
Investor Relations
Latest news
Karyopharm to Present Selinexor D…
Published
Nov 4, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
KPTI -75.3% -94.3% -99.8% -97.3% -99.8%
SPY -0.9% -1.3% +2.3% +0.5% +11.4%
vs SPY -74.4% -93.0% -102.1% -97.8% -111.2%
Key facts CIK 1503802 CUSIP 48576U205 13F (30d) 102 filings 86 filers Visit website Investor relations